These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21862536)

  • 21. A poke in the eye.
    Gurney M
    Nurs Older People; 2007 Dec; 19(10):3. PubMed ID: 18220056
    [No Abstract]   [Full Text] [Related]  

  • 22. Age-related macular degeneration: treatment at what cost?
    The Lancet
    Lancet; 2018 Sep; 392(10153):1090. PubMed ID: 30303068
    [No Abstract]   [Full Text] [Related]  

  • 23. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?
    Harvey KJ; Day RO; Campbell WG; Lipworth W
    Med J Aust; 2011 Jun; 194(11):567-8. PubMed ID: 21644867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AMD: out of sight out of mind.
    Pountney D
    Nurs Older People; 2007 Dec; 19(10):16-9. PubMed ID: 18220063
    [No Abstract]   [Full Text] [Related]  

  • 25. Cancer drug offers effective, cheaper option for AMD.
    Stephenson J
    JAMA; 2011 May; 305(20):2053-4. PubMed ID: 21610231
    [No Abstract]   [Full Text] [Related]  

  • 26. [A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)].
    Holz FG
    MMW Fortschr Med; 2007 Jan; 149(3):13-4. PubMed ID: 17619376
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab in ophthalmology: the controversy moves forward.
    Gillies MC
    Clin Exp Ophthalmol; 2010 May; 38(4):333-4. PubMed ID: 20642588
    [No Abstract]   [Full Text] [Related]  

  • 29. Study aims to clarify efficacy, safety of eye drug treatments.
    Mitka M
    JAMA; 2007 Apr; 297(14):1538-9. PubMed ID: 17426265
    [No Abstract]   [Full Text] [Related]  

  • 30. Bevacizumab versus ranibizumab: why are we not playing the joker?
    Banfi R; Attanasio F; Palazzi N; Colombini S; Falai T; Cecchi M; Virgili G
    Int J Clin Pharm; 2013 Aug; 35(4):507-9. PubMed ID: 23625322
    [No Abstract]   [Full Text] [Related]  

  • 31. Primary care trusts reverse advice to ophthalmologists to use cheaper drug for wet age related macular degeneration.
    Hawkes N
    BMJ; 2012 Jul; 345():e5161. PubMed ID: 22846417
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice.
    Studnička J; Říhová B; Rencová E; Rozsíval P; Dubská Z; Chrapek O; Kolář P; Kandrnal V; Demlová R; Pitrová Š; Řehák J
    Ophthalmologica; 2013; 230(1):34-42. PubMed ID: 23751929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions.
    Messori A; Fadda V; Trippoli S
    Am J Ophthalmol; 2010 May; 149(5):867; author reply 867. PubMed ID: 20399931
    [No Abstract]   [Full Text] [Related]  

  • 34. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
    Li H; Li X; Xie F
    Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):426-33. PubMed ID: 25241975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the real cost of bevacizumab for patients with advanced bowel cancer?
    Dixon L
    Int J Palliat Nurs; 2010 Dec; 16(12):577. PubMed ID: 21240100
    [No Abstract]   [Full Text] [Related]  

  • 36. Minister rules out use of Avastin over Lucentis for wet AMD.
    Kmietowicz Z
    BMJ; 2015 Apr; 350():h2050. PubMed ID: 25882175
    [No Abstract]   [Full Text] [Related]  

  • 37. Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age-related macular degeneration.
    Wickremasinghe S; Abedi F; Sandhu SS; Guymer R
    Clin Exp Ophthalmol; 2013 Nov; 41(8):723-6. PubMed ID: 24152187
    [No Abstract]   [Full Text] [Related]  

  • 38. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Subramanian ML; Ness S; Abedi G; Ahmed E; Daly M; Feinberg E; Bhatia S; Patel P; Nguyen M; Houranieh A
    Am J Ophthalmol; 2009 Dec; 148(6):875-82.e1. PubMed ID: 19800611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
    Chen G; Li W; Tzekov R; Jiang F; Mao S; Tong Y
    Retina; 2015 Feb; 35(2):187-93. PubMed ID: 25105318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ranibizumab for age-related macular degeneration.
    Trempe C
    N Engl J Med; 2011 Feb; 364(6):581-2. PubMed ID: 21306264
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.